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BAG3 induction is required to mitigate proteotoxicity via
selective autophagy following inhibition of constitutive protein
degradation pathways
F Rapino1, M Jung2 and S Fulda1
Simultaneous inhibition of the two major constitutive protein quality control (PQC) pathways, that is, the ubiquitin-proteasome
system (UPS) and the aggresome-autophagy system, has been suggested as a promising strategy to trigger cell death in cancer
cells. However, we observed that one third of rhabdomyosarcoma (RMS) cells survives parallel inhibition of the UPS by Bortezomib
and the aggresome-autophagy pathway by the cytoplasmic histone deacetylase 6 inhibitor ST80, and is able to regrow upon drug
removal, thus pointing to the induction of compensatory pathways. Here, we identify Bcl-2-associated athanogene 3 (BAG3) as a
critical mediator of inducible resistance in surviving cells after concomitant blockage of constitutive PQC pathways by mitigating
ST80/Bortezomib-triggered proteotoxicity via selective autophagy. ST80/Bortezomib cotreatment upregulates BAG3 mRNA and
protein levels in surviving cells in addition to triggering the accumulation of insoluble protein aggregates. Intriguingly, knockdown
of BAG3 by RNA interference severely impairs clearance of protein aggregates, signiﬁcantly increases cell death and reduces long-
term survival and clonogenic growth during recovery after ST80/Bortezomib cotreatment. Similarly, inhibition of autophagy by
inducible autophagy-related protein 7 knockdown prevents removal of protein aggregates and cell regrowth during recovery after
ST80/Bortezomib cotreatment. Also, the inhibition of lysosomal degradation using the V-ATPase pump inhibitor Baﬁlomycin A1
enhances accumulation of protein aggregates, and completely abolishes regrowth after Bortezomib/ST80-induced proteotoxic
stress. By identifying BAG3 as a key mediator of inducible resistance by mitigating proteotoxicity via selective autophagy after
inhibition of constitutive PQC systems, our study provides new insights into the regulation of PQC pathways in cancer cells and
identiﬁes new targets for therapeutic intervention.
Oncogene (2014) 33, 1713–1724; doi:10.1038/onc.2013.110; published online 6 May 2013
Keywords: BAG3; autophagy; proteasome inhibitor; HDAC6; cancer
INTRODUCTION
Protein quality control (PQC) is tightly regulated in mammalian
cells by both constitutive and inducible systems in order to avoid
proteotoxicity of accumulated misfolded or insoluble proteins,
and to sustain cellular growth.1 Under basal conditions, PQC is
predominately carried out by the following two mechanisms: First,
the ubiquitin-proteasome system (UPS) is responsible for the
degradation of linearized and ubiquitin-tagged proteins.1 Second,
the aggresome-autophagy system mediates degradation of
insoluble protein aggregates and aggresomes.1 In the
aggresomal-autophagic degradation pathway, the cytoplasmic
histone deacetylase 6 (HDAC6) is required for the dynein-
mediated, retrograde transport of protein aggregates along
microtubules to the microtubule organizing center to form
aggresomes by binding to ubiquitin-tagged proteins and by
deacetylating a-tubulin.2 In addition, HDAC6 is necessary for
autophagosomal maturation and the clearance of protein
aggregates and aggresomes via autophagy. To this end, HDAC6
recruits cortactin via deacetylation, thereby promoting the
formation of an F-actin network that supports autophagosome-
lysosome fusion.3
Autophagy is an evolutionarily conserved, ubiquitous and multi-
step process, by which cytosolic material is sequestered in a double-
layered membrane, delivered to the lysosome for degradation and
recycled to fuel cellular growth.4 Autophagy starts with the
formation of an isolation membrane, a double membrane
structure also called phagophore, which then encapsulates
cytoplasmatic cargo, seals to form the autophagosome and
eventually fuses with lysosomes to generate autophagolysosomes,
where the cargo is broken down into its constituent components.4
While autophagy has for long been considered as a bulk
degradation process, the recent discovery of several autophagy
receptor proteins, including p62 revealed that autophagy can also
occur in a selective manner.5 p62 links protein aggregates to the
autophagic machinery by binding on one side via its ubiquitin-
associated domain to ubiquitin-tagged proteins and on the other
side via its LC3-interacting region domain to the autophagosomal
membrane protein LC3-II.6 By recruiting protein aggregates or
aggresomes as cargo to autophagic membranes to form
autophagosomes, p62 promotes their degradation.6 In addition,
p62 itself is a substrate for autophagic degradation and accumulates
upon inhibition of autophagy.6
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When constitutive PQC is compromised, the inducible branch of
PQC is usually activated as an on-demand, compensatory
mechanism to ensure PQC.7 For example, during aging when
the activity of the proteasome declines, a transcriptional switch
from Bcl-2-associated athanogene 1 (BAG1)-regulated protein
degradation via the proteasome to BAG3-dependent selective
autophagy has recently been described.8 BAG3 is a co-chaperone
of the BAG family (BAG1-6) and binds to chaperone proteins such
as HSP70 and HSPB8, which allows the recognition and binding to
misfolded substrates.9 Furthermore, BAG3 stimulates substrate
transfer from HSP70 to the dynein motor complex by acting as a
nucleotide-exchange factor, thereby facilitating the dynein-
mediated retrograde transport of misfolded proteins to the
microtubule organizing center to form aggresomes.8 In addition,
BAG3 promotes selective autophagy via its interaction with p62.8
Given the importance of proper PQC to maintain cell viability,
these pathways have been exploited as therapeutic targets in
oncology.10 For example, Bortezomib, a reversible proteasome
inhibitor, demonstrated potent in vitro and in vivo antitumor
activity against various hematological malignancies and solid
cancers, and is approved for the treatment of certain tumors, for
example, multiple myeloma.10 However, several cancers exhibit
primary or acquired resistance to Bortezomib-based therapies,
thus calling for new strategies to bypass this resistance. For
example, engagement of the aggresome-autophagy system has
been encountered as a defense mechanism to compensate as
alternative constitutive PQC pathway for inhibition of the UPS.
Therefore, proteasome inhibitors have been combined with HDAC
inhibitors to concomitantly inhibit the two key constitutive protein
degradation pathways in order to increase the antitumor activities
of proteasome inhibitors.11–13
In rhabdomyosarcoma (RMS), the most common pediatric soft
tissue tumor, initial studies showed that Bortezomib triggers cell
death in vitro and in vivo.14 Therefore, we used RMS cells as a
model to study the regulation of constitutive and inducible
protein degradation pathways. Speciﬁcally, we asked whether
simultaneous inhibition of both the UPS and the aggresome-
autophagy pathway, in addition to synergistically inducing cell
death, engages inducible PQC pathways as escape mechanism in
surviving cells in order to overcome proteotoxicity.
RESULTS
A subpopulation of RMS cells survives and recovers after ST80/
Bortezomib cotreatment
Initially, we asked whether simultaneous inhibition of the two
major protein degradation pathways, that is, the UPS and the
aggresome-autophagy system, co-operates to trigger cell death in
RMS cells via increased proteotoxic stress. To address this
question, we used the effect of the proteasome inhibitor
Bortezomib and the selective HDAC6 inhibitor ST80.15
Importantly, the addition of ST80 signiﬁcantly increased
Bortezomib-induced apoptosis in different RMS cell lines as
determined by DNA fragmentation as a parameter of apoptosis
(Figure 1a). In contrast to RMS cells, ST80 did not enhance
Bortezomib-induced cell death in non-transformed human ﬁbro-
blasts (Figure 1a), pointing to some tumor selectivity.
In addition to this co-operative induction of cell death upon
cotreatment with ST80/Bortezomib, we also noticed that a
substantial subpopulation (about one third) survived cotreatment
with ST80/Bortezomib (Figure1b). To explore whether these
surviving cells were able to recover upon drug removal, we
monitored cell viability for several days after the removal of ST80
and Bortezomib (Supplementary Figure S1a), which are reversible
inhibitors, using both an embryonal (RD) and alveolar (RMS13)
RMS cell line. Interestingly, cells that survived cotreatment with
ST80/Bortezomib regrew after drug removal at a similar rate
as untreated cells (Figure 1c). This suggests that a defense
mechanism is induced in response to treatment with ST80/
Bortezomib, which decreases proteotoxicity and supports cell
recovery. In the present study, we therefore aimed at identifying
the molecular basis of this inducible escape mechanism.
ST80/Bortezomib cotreatment triggers accumulation of insoluble
protein aggregates
As inhibition of the proteasome or HDAC6 has previously been
shown to cause accumulation of ubiquitin-positive, insoluble
protein aggregates,16,17 we analyzed protein aggregates upon
treatment with ST80 and/or Bortezomib by fractioning cell lysates
in TritonX-100 soluble and insoluble fractions. Of note, we
detected a marked increase of ubiquitinated protein aggregates
in the insoluble fraction in cells cotreated with ST80/Bortezomib
(Figure 2a). In parallel, ST80/Bortezomib cotreatment caused an
increase of p62 protein levels in the insoluble fraction, a typical
substrate of autophagic degradation (Figure 2a). Also, we used the
ﬁlter trap assay as an alternative method to analyze protein
aggregates. Similarly, cotreatment with ST80/Bortezomib caused
accumulation of ubiquitin-positive protein aggregates compared
with treatment with ST80 or Bortezomib alone (Supplementary
Figure S1b).
To investigate whether this accumulation of protein aggregates
is due to dysfunction of autophagy in surviving cells, we assessed
the conversion of LC3 from the cytosolic form, that is LC3-I, to the
autophagosome-associated form, that is, LC3-II. Of note, the
conversion of LC3-I to LC3-II was not impaired in ST80/
Bortezomib-cotreated cells (Figure 2b) despite the observed
defect in the clearance of protein aggregates (Figure 2a). To
further evaluate autophagic functions, we examined lysosomal
activity by Lysotracker Red staining. Bortezomib similarly stimu-
lated lysosomal acidiﬁcation in the presence and absence of ST80
(Figure 2c, Supplementary Figure S1c), demonstrating that ST80
does not impair Bortezomib-mediated lysosomal acidiﬁcation.
Taken together, these ﬁndings show that ST80/Bortezomib
cotreatment triggers the accumulation of insoluble protein
aggregates and p62 protein in the subpopulation of cells that
survive ST80/Bortezomib cotreatment without impairing the
formation of autophagosomes or lysosomal acidiﬁcation. This
points to defective clearance of protein aggregates by the
ongoing autophagy, consistent with impaired transport and
removal of protein aggregates upon inhibition of the UPS and
HDAC6.
BAG3 is upregulated upon ST80/Bortezomib cotreatment
As ST80/Bortezomib cotreatment triggers accumulation of poten-
tially toxic protein aggregates, we hypothesized that the
cotreatment simultaneously engages a rescue mechanism in
surviving cells to mitigate proteotoxic stress, thereby allowing
cells to recover. As the co-chaperone BAG3 has been reported to
be upregulated when proteasomal function declines during
aging,8 we analyzed BAG3 expression levels. Intriguingly, ST80/
Bortezomib cotreatment strongly co-operated to increase BAG3
mRNA and protein levels in the subpopulation of RMS cells
that survived ST80/Bortezomib cotreatment (Figures 3a–c,
Supplementary Figure S2b). Kinetic analysis revealed a delayed
increase of BAG3 mRNA levels starting about 30–42 h upon
treatment with ST80/Bortezomib (Figure 3d). In contrast to RMS
cells, no co-operative upregulation of BAG3 mRNA or protein
levels by ST80/Bortezomib cotreatment was observed in non-
malignant human ﬁbroblasts, whereas treatment with Bortezomib
alone resulted in a slight increase in BAG3 mRNA or protein
expression (Supplementary Figures S2a and b).
To conﬁrm the speciﬁcity of BAG3 upregulation, we determined
in parallel mRNA levels of the co-chaperone BAG1, which has been
implicated in protein degradation via the proteasome.18 In
contrast to the marked upregulation of BAG3, ST80/Bortezomib
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cotreatment minimally altered BAG1 mRNA expression (Figure 3a–c).
To exclude that BAG3 is simply upregulated as an unspeciﬁc
stress response to the induction of cell death, we also analyzed
BAG3 expression upon treatment with two prototypic apoptotic
stimuli, that is, the TRAIL receptor 2 agonistic antibody
Lexatumumab, which induces apoptosis in RMS cells via the
death receptor (extrinsic) pathway of apoptosis,19 and the BH3
(Bcl-2 homology domain 3) mimetic ABT-737 that engages the
mitochondrial (intrinsic) pathway of apoptosis. Neither treatment
with Lexatumumab nor with ABT-737 upregulated BAG3 mRNA
levels, although both agents triggered DNA fragmentation to a
similar extent compared with ST80/Bortezomib (Supplementary
Figures S2c–f). This indicates that BAG3 upregulation is not simply























































































































































































































Figure 1. A subpopulation of RMS cells survives and recovers after ST80/Bortezomib cotreatment. (a) RMS cells were treated for 48 h with
indicated concentrations of Bortezomib and/or 50 mM ST80. BJ fibroblasts were treated for 48 h with 20 nM Bortezomib and/or 50 mM ST80.
Apoptosis was determined by fluorescence-activated cell-sorting (FACS) analysis of DNA fragmentation of propidium iodide-stained nuclei.
(b) RD and RMS13 cells were treated for 48 h with 20 nM (RD) or 50 nM (RMS13) Bortezomib in the presence or absence of 50 mM ST80. Cell
viability was measured by crystal violet staining and is expressed as fold change of untreated cells. (c) RD and RMS13 cells were treated for
48 h with 20 nM (RD) or 50 nM (RMS13) Bortezomib in the presence or absence of 50 mM ST80, after treatment for 48 h drugs were removed (day
0), and cells were grown in fresh, drug-free medium up to 3 days. Cell viability was measured at indicated time points by crystal violet staining.
In (a–c) meanþ s.d. of three independent experiments performed in triplicate are shown; *Po0.05; **Po0.001 comparing cells treated with
Bortezomib in the absence and presence of ST80; n.s., not significant.
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Together, these data demonstrate that BAG3 is speciﬁcally
upregulated in cells which survive proteotoxic stress upon ST80/
Bortezomib cotreatment, suggesting that BAG3 may act as a
compensatory mechanism to clear protein aggregates upon
concomitant inhibition of the proteasome and HDAC6.
BAG3 is required for the clearance of protein aggregates during
cell recovery
To investigate whether BAG3 is required for clearing protein
aggregates after ST80/Bortezomib cotreatment, we stably
knocked down BAG3 by short hairpin RNA (shRNA) vectors. As
control, we used a RNA sequence with no corresponding
counterpart in the human genome. All three shRNA vectors
targeting BAG3 caused downregulation of constitutive BAG3
mRNA and protein levels (Supplementary Figures S3a and b). In
addition, silencing of BAG3 prevented the upregulation of BAG3
expression upon ST80/Bortezomib treatment and during the
recovery phase after drug removal compared with control vector
cells, which maintained high BAG3 levels for several days after
drug removal (Figure 4a, Supplementary Figure S3c). Also, we
conﬁrmed that BAG3 knockdown did not result in compensatory
upregulation of BAG1 levels (Supplementary Figure S3d). To
explore whether BAG3 is required for the clearance of protein
aggregates during cell recovery, we assessed the amount of
protein aggregates and p62 protein at the time of drug removal
after cotreatment with ST80/Bortezomib for 48 h (that is, day 0 of
recovery) and 2 or 3 days later. Cotreatment with ST80/Bortezomib
for 48 h caused comparable accumulation of ubiquitin-positive
protein aggregates and p62 protein levels in the insoluble fraction
in BAG3 knockdown and control cells (Figure 4b), consistent with
the delayed kinetic of BAG3 upregulation starting 30–42 h upon
ST80/Bortezomib treatment (Figure 3d). Importantly, in the
recovery phase 2 or 3 days after removal of ST80/Bortezomib,
silencing of BAG3 caused a marked increase both in protein
aggregates and in p62 protein levels in the insoluble fraction
compared with control cells (Figure 4c). Similarly, the ﬁlter
trap assay conﬁrmed that BAG3 knockdown cells maintained
higher levels of insoluble protein aggregates 3 days after
































































































































Figure 2. ST80/Bortezomib cotreatment triggers accumulation of insoluble protein aggregates. RD and RMS13 cells were treated for 48 h with
20 nM (RD) or 50 nM (RMS13) Bortezomib and/or 50 mM ST80. (a) Ubiquitin-positive protein aggregates were assessed by western blot analysis
after fractionation of total viable cells in TritonX-100 (TX-100) into soluble and insoluble fractions. GAPDH and histone 3 were used as loading
and purity controls for soluble and insoluble fractions, respectively. (b) Autophagosome formation was determined by LC3-I/LC3-II conversion
using western blot analysis. b-Actin was used as loading control. (c) Lysosomal acidification was quantified by FACS analysis of lysotracker
RED-stained cells. Meanþ s.d. of three independent experiments performed in triplicate are shown.
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levels of ubiquitin-positive protein aggregates were comparable in
BAG3 knockdown and control cells after cotreatment with
ST80/Bortezomib for 48 h at day 0 of recovery (Supplementary
Figure S3c).
This set of experiments shows that BAG3 is critically required for
the clearance of protein aggregates during cell recovery after
ST80/Bortezomib cotreatment.
BAG3 is necessary for cell recovery after ST80/Bortezomib
cotreatment
Next, we investigated the question whether BAG3 is necessary to
mitigate the cytotoxicity of protein aggregates after ST80/
Bortezomib cotreatment. To this end, we monitored cell regrowth
during recovery after removal of ST80/Bortezomib in BAG3
knockdown and control cells. Strikingly, BAG3 knockdown cells
completely failed to regrow during the recovery phase, resulting
in reduced cell viability at day 10 compared with day 0 of the
recovery phase (Figure 5a). In sharp contrast, shRNA control cells,
which upregulated BAG3 upon ST80/Bortezomib treatment
(Figure 4a), regrew by several folds upon drug removal
(Figure 5a). No signiﬁcant differences in cell regrowth during
recovery were observed between BAG3 knockdown and control
cells treated with either ST80 or Bortezomib alone compared with
untreated cells (Supplementary Figure S4a), in line with our
ﬁndings that BAG3 is predominately upregulated in cells exposed
to ST80/Bortezomib cotreatment (Figure 3a–c). To explore






































































































































































Figure 3. BAG3 is upregulated upon ST80/Bortezomib cotreatment. (a–c) RMS cells were treated for 48 h with 20 nM (RD) or 50 nM (RMS13,
TE671) Bortezomib and/or 50mM ST80. mRNA levels of BAG1 and BAG3 were assessed by quantitative reverse transcription PCR (qRT–PCR).
BAG3 protein levels were determined by western blot analysis. b-Actin was used as loading control. (d) RD and RMS13 cells were treated with
20 nM (RD) or 50 nM (RMS13) Bortezomib and 50mM ST80 for indicated times. mRNA levels of BAG1 and BAG3 were assessed by qRT-PCR.
Meanþ s.d. of three independent experiments performed in triplicate are shown.
BAG3 mitigates proteotoxicity via selective autophagy
F Rapino et al
1717
& 2014 Macmillan Publishers Limited Oncogene (2014) 1713 – 1724
due to the induction of apoptosis we measured in parallel DNA
fragmentation. As shown in Figure 5b, BAG3 knockdown cells
exhibited signiﬁcantly higher amounts of DNA fragmentation 3
days after removal of ST80/Bortezomib compared to control cells.
To examine the effect of BAG3 on clonogenic survival, we
determined single cell clonogenic growth during recovery after
ST80/Bortezomib cotreatment. To this end, BAG3 knockdown and
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Figure 4. BAG3 is required for the clearance of protein aggregates during cell recovery. RD and RMS13 cells transduced with control vector
(shCtrl) or vectors containing three different shRNA sequences against BAG3 were treated for 48 h with 20 nM (RD) or 50 nM (RMS13)
Bortezomib and 50 mM ST80 (BS) before treatment was removed (day 0) and cells were grown in fresh, drug-free medium up to 3 days. (a) Total
BAG3 protein levels were detected by western blot analysis. GAPDH was used as loading control. (b and c) Ubiquitin-positive protein
aggregates were assessed by western blot analysis after fractionation of total viable cells in TX-100 into soluble and insoluble fractions.
GAPDH and histone 3 were used as loading and purity controls for soluble and insoluble fractions, respectively.
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surviving cells were seeded as single cells in drug-free medium
and the number of colonies was assessed after 14 days.
Importantly, BAG3 knockdown signiﬁcantly reduced colony
formation of cells that survived ST80/Bortezomib cotreatment
compared with control vector cells (Figures 5c and d). No
signiﬁcant difference in colony formation was detectable
between untreated BAG3 knockdown and control vector cells
(Figure 5c), indicating that basal BAG3 levels are dispensable
for colony growth of RMS cells in the absence of proteotoxic
stress. Also, BAG3 knockdown did not alter ST80/Bortezomib-
induced apoptosis during the initial 48 h treatment period with
ST80/Bortezomib compared with control cells (Supplementary
Figure S4b), in line with the delayed kinetic of BAG3 upregulation
starting 30–42h of ST80/Bortezomib treatment (Figure 3d).
This set of experiments demonstrates that BAG3 is critically
required during the recovery phase after ST80/Bortezomib
cotreatment to support cell regrowth and clonogenic survival
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Figure 5. BAG3 is necessary for cell recovery after ST80/Bortezomib cotreatment. RD and RMS13 cells transduced with control vector (shCtrl)
or vectors containing three different shRNA sequences against BAG3 were treated for 48 h with 20 nM (RD) or 50 nM (RMS13) Bortezomib and
50mM ST80 (BS) before treatment was removed (day 0), and cells were grown in fresh, drug-free medium. (a) Cell viability was measured at
indicated time points by crystal violet staining. (b) Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide-
stained nuclei. (c and d) After 48 h treatment with ST80/Bortezomib cells were seeded as single cells and grown in drug-free medium for 14
days before colony formation was assessed by crystal violet staining and colonies were counted under the microscope. The number of
colonies (c) and representative images (d) are shown. Meanþ s.d. of three independent experiments performed in triplicate (a and b) or
duplicate (c) are shown; *Po0.05; **Po0.001 comparing shCtrl and shBAG3 cells.
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Inhibition of autophagosome formation impairs clearance of
protein aggregates and recovery of cells surviving ST80/
Bortezomib cotreatment
As BAG3-mediated clearance of protein aggregates has previously
been associated with selective autophagy,20 we hypothesized that
autophagy is required for the removal of protein aggregates after
ST80/Bortezomib treatment. To address this question, we
interfered with the induction of autophagy selectively during
the recovery phase after drug removal of ST80/Bortezomib by
generating cells with inducible knockdown of autophagy-related
protein 7 (ATG7). Downregulation of ATG7 was detectable after
48 h exposure to doxycycline (that is, day 0 of recovery) and
sustained at least for up to 120 h (that is, day 3 of recovery;
Figure 6a, Supplementary Figure S5a). Downregulation of ATG7
was accompanied by reduced LC3-II conversion (Figure 6a),
demonstrating that ATG7 knockdown impairs autophagosome
formation under basal conditions. Importantly, ATG7 knockdown
substantially delayed the clearance of protein aggregates and of
p62 protein at day 2 and 3 of recovery after ST80/Bortezomib
cotreatment compared with control cells (Figure 6b). Also,
silencing of ATG7 signiﬁcantly impaired cell regrowth during
recovery after ST80/Bortezomib cotreatment compared with
control cells, resulting in a substantial reduction of cell viability
at day 2 and 3 compared with day 0 of the recovery period
and increased apoptosis (Figures 6c and d). In contrast, control
cells showed a marked increase in cell growth and reduced
apoptosis upon drug removal (Figures 6c and d). By comparison,
cells with inducible ATG7 knockdown showed no differences in
ST80/Bortezomib-triggered apoptosis or loss of cell viability
compared with control cells during the initial treatment
with ST80 and Bortezomib for 48 h (Supplementary Figures S5d
and e), in line with the delayed kinetic of ATG7 downregulation
observed 48 h after the addition of doxycycline (Supplementary
Figure S5a).
As a side note, we detected a slight but signiﬁcant decrease in
basal cell growth in ATG7 knockdown compared with control cells
also in the absence of ST80/Bortezomib (Supplementary Figure
S5b), in line with the role of basal autophagy in maintaining
cancer cell viability. However, this slight difference in constitutive
cell growth cannot fully explain the marked difference in cell
viability between ATG7 knockdown and control cells at day 3 of
recovery after ST80/Bortezomib cotreatment (Supplementary
Figure S5b, Figure 6c). This indicates that autophagy is required
to support viability of RMS cells in particular after proteotoxic
stress and to some extent under basal conditions.
Together, this set of experiments shows that inhibition of
autophagosome formation prevents clearance of protein aggre-
gates and impairs cell regrowth during recovery after ST80/
Bortezomib cotreatment similarly to silencing of BAG3.
Inhibition of lysosomal degradation impairs clearance of protein
aggregates and recovery of cells surviving ST80/Bortezomib
cotreatment
Finally, we investigated the requirement of the aggresome-
autophagy system for cell recovery after ST80/Bortezomib
cotreatment by inhibiting lysosomal degradation, which is
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Figure 6. Inhibition of autophagosome formation impairs clearance of protein aggregates and recovery of cells surviving ST80/Bortezomib
cotreatment. RD cells were transduced with an inducible vector containing a shRNA sequence against ATG7 (shATG7) or control vector
(shCtrl). (a) Knockdown efficiency was evaluated at indicated time points by western blot analysis of ATG7 and LC3-I/II conversion after
treatment with 1 mg/ml doxycycline. b-Actin was used as loading control. (b–d) Cells were treated with 20 nM Bortezomib and 50mM ST80 for
48 h (BS) before treatment was removed (day 0), and cells were grown in fresh, drug-free medium up to 3 days. In (b), ubiquitin-positive
protein aggregates were assessed by western blot analysis after fractionation of total viable cells in TX-100 into soluble and insoluble
fractions. GAPDH and histone 3 were used as loading and purity controls for soluble and insoluble fractions, respectively. In (c), cell viability
was measured at indicated time points by crystal violet staining. In (d), apoptosis was determined by FACS analysis of DNA fragmentation of
propidium iodide-stained nuclei. Meanþ s.d. of three independent experiments performed in triplicate are shown; **Po0.001 comparing
control to ATG7 knockdown cells.
BAG3 mitigates proteotoxicity via selective autophagy
F Rapino et al
1720
Oncogene (2014) 1713 – 1724 & 2014 Macmillan Publishers Limited
end, we used Baﬁlomycin A1 (BafA1), a speciﬁc V-ATPase inhibitor
that blocks lysosomal acidiﬁcation and thereby lysosomal
degradation. Of note, the addition of BafA1 substantially impaired
clearance of insoluble protein aggregates during recovery at days
2 and 3 after removal of ST80/Bortezomib, accompanied by an
increase of p62 protein levels (Figure 7a). Importantly, BafA1
signiﬁcantly reduced cell regrowth and increased apoptosis after
ST80/Bortezomib treatment (Figures 7b and c). These ﬁndings
conﬁrm that a functional autophagic/lysosomal degradation
system is required for the removal of protein aggregates and cell
regrowth during recovery after ST80/Bortezomib treatment.
DISCUSSION
Concomitant inhibition of constitutive protein degradation path-
ways using proteasome and HDAC inhibitors has recently been
suggested as a promising strategy to trigger cancer cell death via
enhanced proteotoxicity.21 As we observed that a substantial
subpopulation of RMS cells survives this cotreatment and can
even recover and regrow after drug removal, we investigated the
underlying escape mechanism in the current study. Here, we
identify the co-chaperone BAG3 as a key mediator of inducible
resistance after ST80/Bortezomib-induced proteotoxic stress that
mitigates proteotoxicity by promoting clearance of protein
aggregates via autophagy. This conclusion is supported by several
independent lines of evidence (Figure 8). First, ST80 and Bortezomib
co-operatively upregulate BAG3 mRNA and protein levels in RMS
cells, which survive ST80/Bortezomib cotreatment, in parallel with
the accumulation of insoluble, ubiquitin-positive protein aggregates.
Second, BAG3 is critically required to clear protein aggregates and to
support cell regrowth during the recovery period after removal of
ST80/Bortezomib by engaging autophagy, as BAG3 knockdown
severely impairs clearance of protein aggregates, signiﬁcantly
increases cell death and reduces long-term viability and clonogenic
growth during recovery. Third, blockage of the autophagic pathway,
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Figure 7. Inhibition of lysosomal degradation impairs clearance of protein aggregates and recovery of cells surviving ST80/Bortezomib
cotreatment. RD and RMS13 cells were treated for 48 h with 20 nM (RD) or 50 nM (RMS13) Bortezomib and 50 mM ST80 (BS) before treatment was
removed (day 0), and cells were grown in fresh medium with or without 5 nM Bafilomycin A1 up to 3 days. (a) Ubiquitin-positive protein
aggregates levels were assessed by western blot analysis after fractionation of total viable cells in TX-100 into soluble and insoluble fractions.
GAPDH and histone 3 were used as loading and purity controls for soluble and insoluble fractions, respectively. (b) Cell viability was measured
at indicated time points by crystal violet staining. (c) Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide-
stained nuclei. Meanþ s.d. of three independent experiments performed in triplicate are shown; **Po0.001 comparing cells in the presence
and absence of Bafilomycin A1.
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knockdown or by pharmacological inhibition of lysosomal degrada-
tion using the V-ATPase pump inhibitor BafA1, impairs the clearance
of protein aggregates and signiﬁcantly reduces cell regrowth during
recovery upon drug removal. Thus, BAG3-mediated selective auto-
phagy serves as an on-demand, compensatory PQC pathway that is
induced upon simultaneous inhibition of the two major constitutive
protein degradation pathways, and critically required to mitigate
proteotoxic stress by removing accumulated protein aggregates.
BAG3 has been described to promote protein degradation via
the aggresome/autophagy pathway via interaction with several
proteins involved in this process.22 As co-chaperone, it mediates the
recognition and binding of the HSPB8-HSP70-CHIP-BAG3
multichaperone complex to misfolded proteins.9 Also, BAG3
interacts with dynein and stimulates substrate transfer from
HSP70 to the dynein motor complex via its nucleotide-exchange
factor activity, thereby promoting the retrograde transport of
misfolded proteins along microtubules to the microtubule
organizing center to form insoluble protein aggregates and
aggresomes.8 Furthermore, BAG3 binds to the selective
autophagy receptor p62 that links ubiquitinated substrates to the
autophagy marker protein LC3 on autophagosomal membranes,
thereby targeting misfolded proteins to autophagosomes for their
degradation via selective autophagy.8 Also, BAG3 has recently been
reported to mediate selective autophagy of misfolded proteins
independently of substrate ubiquitination.23
The novelty of our study resides in particular in the identiﬁca-
tion of BAG3 as a key mediator of an inducible, compensatory PQC
pathway to support RMS cell survival in response to concomitant
blockade of basal PQC pathways by ST80/Bortezomib cotreat-
ment. Concomitant pharmacological inhibition of the proteasome
and HDAC6 has recently been suggested to be superior to
treatment with proteasome inhibitors alone to trigger cell death in
cancer cells, as inefﬁcient degradation by one of the two major
constitutive pathways for protein turnover is often compensated
by increased protein degradation by the other system.21 To this
end, proteasome inhibitors such as Bortezomib together with
HDAC inhibitors have demonstrated synergistic cytotoxicity in
several cancers, for example, ovarian, breast and colon
carcinoma.11–13 Although we similarly show in RMS that
cotreatment with ST80 and Bortezomib co-operates to trigger
cell death, our present study focused on the surviving, but not the
dying cell subpopulation, as we aimed at identifying the
mechanism of acquired resistance to ST80/Bortezomib-induced
proteotoxic stress. Notably, we demonstrate for the ﬁrst time that
BAG3-mediated autophagy is turned on as a compensatory
pathway upon concomitant inhibition of the proteasome and
HDAC6 that is required for clearance of protein aggregates and
cell regrowth during recovery after proteotoxic stress. This
indicates that BAG3 upregulation represents an important
inducible resistance mechanism in the context of therapeutic
inhibition of the two major constitutive protein degradation
pathways in cancer cells. Of note, our data show that BAG3 is
necessary to support the survival of RMS cells during the recovery
phase after drug removal, while it is dispensable during the initial
48 h treatment period with ST80/Bortezomib. This differential role
of BAG3 during the recovery period is consistent with the delayed
kinetic of BAG3 upregulation in our experiments, as BAG3 mRNA
levels start to increase upon 30–42 h of exposure to ST80/
Bortezomib. Although NF-kB activity has been implicated in
transcriptional upregulation of BAG3 after heat shock,24 additional
studies are required to explore the question whether this
transcriptional factor is involved in the current model.
Constitutive BAG3 expression has been detected in several
types of human cancers, such as glioblastoma, pancreatic
carcinoma, leukemia and thyroid carcinoma, compared with very
low basal levels of BAG3 in non-malignant cells.25–28 Previously,
BAG3 has been reported to support cancer cell survival by
counteracting apoptosis. For example, BAG3 was shown to co-
operate with the chaperone HSP70 to retain Bcl-2-associated
X protein, BAX protein in the cytosol, which in turn prevented








































Figure 8. Scheme of the proposed mechanism. Inhibition of HDAC6 and of the proteasome by ST80/Bortezomib cotreatment co-operates to
trigger cell death and causes accumulation of protein aggregates (red). Cells that survive ST80/Bortezomib cotreatment upregulate BAG3,
which enhances clearance of protein aggregates via the aggresome-autophagy system, thereby decreasing toxicity and promoting cell
recovery (green).
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Bcl-2-associated X protein translocation to the mitochondria and
inhibited cisplatinum- or serum deprivation-induced apoptosis.25
In addition, BAG3 was described to interfere with the
HSP70-mediated delivery of antiapoptotic proteins, such as IKKg,
MCL1, BCL2, BCL-XL to the proteasome by competing with BAG1
that functions as co-chaperone of HSP70 in this process.29–31
Compared with these previous reports on the antiapoptotic
properties of BAG3, we demonstrate in the present study that
BAG3 maintains cancer cell viability by promoting autophagic
clearance of protein aggregates. While BAG3 upregulation has
been described to confer resistance to treatment with proteasome
inhibitors alone,32,33 we found that BAG3 is dispensable for RMS
cell viability upon single agent treatment with Bortezomib, in line
with little upregulation of BAG3 by Bortezomib alone compared
with ST80/Bortezomib cotreatment in our study.
Induction of BAG3 expression has previously been implicated in
other models of PQC during chronic or acute stress due to the
accumulation of misfolded or damaged proteins. For example,
during aging a BAG1/BAG3-switch has been reported to compen-
sate for the age-dependent decrease in the efﬁcacy of BAG1-
mediated proteasomal degradation by engaging BAG3-mediated
autophagy as an on-demand selective autophagy pathway.8
Furthermore, the BAG3-selective autophagy pathway has been
implicated in regulating the removal of misfolded protein
aggregates in neurodegenerative diseases.8,34 In addition,
upregulation of BAG3 was recently shown to mediate the removal
of damaged proteins after heat shock.24 Our present study adds a
new aspect to this concept of BAG3 as an on-demand, inducible
PQC system in situations of acute and chronic stress by showing for
the ﬁrst time that BAG3-mediated selective autophagy is induced
upon concomitant pharmacological blockade of the two major
constitutive branches for protein degradation in cancer cells and
critically required to support the recovery from proteotoxic stress.
Our ﬁndings have important implications for a better under-
standing of the molecular regulation of constitutive and inducible
PQC pathways in cancer cells. As inhibition of protein degradation
is considered as an attractive anticancer strategy,10 further insights
into the mechanisms that regulate sensitivity and resistance of
cancer cells to inhibitors of PQC pathways will be critical to exploit
this strategy in human cancers. By identifying the BAG3-mediated
selective autophagy pathway as a novel mechanism of acquired
resistance that compensates for inhibition of the constitutive
protein degradation systems, our ﬁndings suggest that interfering
with this inducible escape mechanism may potentiate the efﬁcacy
of protein degradation inhibitors. Thus, inhibition of both
inducible and constitutive PQC pathways may open new
perspectives for their therapeutic exploitation in cancers.
MATERIALS AND METHODS
Cell culture and chemicals
RMS cell lines and the human ﬁbroblast cell line BJ were obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells were
maintained in Roswell Park Memorial Institute medium 1640 or Dulbecco’s
Modiﬁed Eagle Medium medium (Life Technologies Inc., Carlsbad, CA,
USA), supplemented with 10% fetal calf serum (Biochrom, Berlin,
Germany), 1mM glutamine (Invitrogen, Karlsruhe, Germany), 1% penicil-
lin/streptomycin (Invitrogen) and 25mM HEPES (Biochrom). Bortezomib
was purchased by Jansen-Cilag (Neuss, Germany); Baﬁlomycin A1 (Baf A1)
from Sigma (Deisenhofen, Germany); Doxycycline monohydrate by Santa
Cruz Biotechnology (Santa Cruz, CA, USA). ST8015 was kindly provided by M
Jung and Lexatumumab, a fully human agonist monoclonal antibody
against TRAIL-R2, by R Humphreys (Human Genome Sciences, Rockville,
MD, USA).35 Chemicals were purchased from Sigma unless otherwise
indicated.
RNA interference
For stable or inducible gene knockdown, HEK293T producer cells were
transfected with 7.5mg pGIPZ-shRNAmir or pTRIPZ-shRNAmir vector (Thermo
Fisher Scientiﬁc, Dreieich, Germany), 12.5mg pCMV-dR8.9136 and 1mg
pMD2.G (Addgene no. 12259) using calcium phosphate transfection as
previously described37 (non-silencing control: RHS4346, shBAG3 no. 1:
RHS4430; shBAG3 no. 3: RHS4430; shBAG3 no. 4: RHS4430; shATG7: RHS4430).
Determination of apoptosis, cell viability, colony formation and
lysosomal acidiﬁcation
Apoptosis was determined by ﬂuorescence-activated cell-sorting analysis of
DNA fragmentation of propidium iodide-stained nuclei as described
previously38 using ﬂuorescence-activated cell-sorting Canto II (BD
Biosciences, Heidelberg, Germany). Cell viability was assessed by crystal
violet staining (0.75% crystal violet, 50% ethanol, 0.25% NaCl, 1.57%
formaldehyde). Crystal violet dye was resolubilized in 1% SDS and
absorbance at 550nM was measured by microplate reader (Inﬁnite M200,
Tecan Group Ltd., Maennedorf, Switzerland). For colony assay, cells were
treated for 48h, re-seeded as single cells (200 cells/well) in six-well plates and
cultured for additional 14 days before colonies were stained with crystal
violet. The number of colonies was counted under the microscope. Lysosomal
acidiﬁcation was determined by staining with 0.05nM Lysotracker Red
(Invitrogen) and ﬂow cytometry according to the manufacturer’s instructions.
Western blot analysis
Western blot analysis was performed as described previously38 using the
following antibodies: rabbit anti-p62/SQSTM1 (MBL, Nagoya, Japan); rabbit
anti-LC3 (Thermo Scientiﬁc, Waltham, MA, USA); rabbit anti-ATG7 and
rabbit anti-BAG3 (AbCam, Cambridge, UK); mouse anti-polyubiquitin
antibody (Millipore, Darmstadt, Germany). Mouse anti-b-Actin (Sigma),
mouse anti-GAPDH (HyTest, Turku, Finland) or rabbit anti-Histone 3
(AbCam) were used as loading controls. Goat anti-mouse immunoglobulin
G and goat anti-rabbit immunoglobulin G conjugated to horseradish
peroxidase (Santa Cruz Biotechnology) as secondary antibodies and
enhanced chemiluminescence were used for detection (Amersham
Bioscience, Freiburg, Germany). Alternatively, infrared dye-labeled
secondary antibodies and infrared imaging were used for detection
(Odyssey imaging system, LI-COR Bioscience, Bad Homburg, Germany).
Representative blots of at least two independent experiments are shown.
Determination of protein aggregates
Protein aggregates were determined by fractioning cell lysates in TritonX-
100 soluble and insoluble fractions as previously described.39 Brieﬂy, cells
were harvested with cold 1x phosphate-buffered saline and collected by
centrifugation (1800 r.p.m.; 5min). Cell pellets were resuspended in 2%
TritonX-100/1x phosphate-buffered saline solution supplemented with
protease and phosphates inhibitors, incubated on ice for 30min. After
centrifugation for 30min at 4 1C and 13 000 r.p.m., the supernatant was
recovered as soluble fraction. Pellets were resuspended in 1% SDS
supplemented with protease and phosphatase inhibitors and sonicated for
20 s. Expression of ubiquitin-positive proteins was determined by western
blot analysis.
Determination of protein aggregates by ﬁlter trap assay was performed as
previously described.40 Brieﬂy, protein lysates were solubilized in 1% SDS
and directly spotted onto nitrocellulose membrane. Vacuum blotting was
performed for 30min by gel dryer (Bio-Rad, Munich, Germany). Expression of
ubiquitin-positive protein aggregates was assessed by staining of the
membrane with mouse anti-polyubiquitin antibody (Millipore), followed by
goat anti-mouse immunoglobulin G secondary antibody conjugated
to horseradish peroxidase (Santa Cruz Biotechnology). Enhanced
chemiluminescence (Amersham Bioscience) was used for detection.
Quantitative reverse transcription PCR
Total RNA was extracted using peqGOLD Total RNA kit from Peqlab
Biotechnologie GmbH (Erlangen, Germany) according to the manufac-
turer’s instructions. Three micrograms of total RNA were used to synthe-
tize the corresponding complementary DNA using RevertAid H Minus
First Strand complementary DNA Synthesis Kit (MBI Fermentas GmbH,
St Leon-Rot, Germany). To quantify gene expression levels, SYBR-Green
based quantitative reverse transcription PCR was performed using the
7900HT fast real-time PCR system from Applied Biosystems (Darmstadt,
Germany) according to manufacturer’s instructions. Data were normalized
on 18S-rRNA expression as reference gene. The following primers
(10 pmol/ml) were used: BAG1-for: 50-TCACCCACAGCAATGAGAAG-30 ;
BAG1-rew: 50-ATTAACATGACCCGGCAACC-30 ; BAG3-for: 50-CTCCATTCCGG
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TGATACACGA-30 ; BAG3-rew: 50-TGGTGGGTCTGGTACTCCC-30 . Melting curves
were plotted to verify the speciﬁcity of the ampliﬁed products. All
determinations were performed in triplicate. The relative expression of the
target gene transcript and reference gene transcript was calculated as
DDCt.
Statistical analysis
Statistical signiﬁcance was assessed by Student’s t-test (two-tailed
distribution, two- sample, unequal variance).
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